Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Modulators of muscarinic receptors claimed by Lilly for AD, psychosis

Jan. 15, 1998

Phthalazine AMPA receptor antagonists claimed by Schering AG

Jan. 15, 1998

Interim results reported for ziconotide phase III pain study

Jan. 15, 1998

Pharmacological profile of parenteral ET antagonist for SAH described by Roche

Jan. 14, 1998

Agents with affinity for 5-HT2 receptors under development at Janssen

Jan. 14, 1998

Serotonergic agents prepared at Merck KGaA as potential antidepressants/anxiolytics

Jan. 14, 1998

PDE IV/TNF production inhibitors claimed by Schering AG for MS

Jan. 14, 1998

Nastech licenses nasal scopolamine to Schwarz

Jan. 14, 1998

Synaptic and Gruenenthal initiate pain collaboration

Jan. 13, 1998

Akzo patents benzylamines for depression

Jan. 13, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...